Effects of cAMP and cGMP-dependent Protein Kinase Inhibitors on TNF Release
Author Information
Author(s): A. Hichami, E. Boichot, N. Germain, E. Berdyshev, O. Coqueret, V. Lagente
Primary Institution: Laboratoire de Pharmacodynamie et de Pharmacologie Molculaire, Université de Rennes 1, France
Hypothesis
The study investigates the role of specific inhibitors of PKA and PKG on the inhibitory activity of PDE type 4 inhibitors and db-cAMP on TNF release from human mononuclear cells.
Conclusion
The study concludes that db-cAMP inhibits TNF release through a PKA-dependent mechanism, while PDE 4 inhibitors act via a PKG-dependent mechanism.
Supporting Evidence
- Incubation with db-cAMP and PDE 4 inhibitors significantly inhibited LPS-induced TNF release.
- The selective PKA inhibitor H89 reduced the inhibitory effect of db-cAMP.
- The selective PKG inhibitor Rp-8-pCPT-cGMPs significantly reduced the inhibitory activities of PDE 4 inhibitors.
Takeaway
This study shows that certain substances can help reduce inflammation in cells by affecting how they respond to signals in the body.
Methodology
Mononuclear cells were isolated and treated with various concentrations of db-cAMP and PDE 4 inhibitors, followed by measurement of TNF release using ELISA.
Participant Demographics
Healthy donors provided the buffy coats for mononuclear cell isolation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website